TScan Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -13.60%
- Market cap
- $11.11M
- 67.78M shares
- Filings
- 336
Q3 2026+266.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−14.7% FY25 yoy
- $11.11M
- —
- 2.1×
- 0.3×
- -1005.20%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $10,325,000 | reported | |
| FY 2024 | 2024-12-31 | $2,816,000 | reported | |
| FY 2023 | 2023-12-31 | $21,049,000 | reported | |
| FY 2022 | 2022-12-31 | $13,535,000 | reported | |
| FY 2021 | 2021-12-31 | $10,141,000 | reported | |
| FY 2020 | 2020-12-31 | $1,085,000 | reported |
Biological products, except diagnostic substances
TScan Therapeutics, Inc. is the 61st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
RLAYRelay Therapeutics, Inc.$15.4M53.4%1,800.6%$4.0BLCTXLineage Cell Therapeutics, Inc.$14.6M53.2%436.5%$250.5MELUTElutia Inc.$12.3M15.0%434.2%$39.8MCRBUCaribou Biosciences, Inc.$11.2M11.7%1,327.4%$40.8M
TCRXTScan Therapeutics, Inc. (this company)$10.3M266.7%1,256.8%$11.1M
ACOGAlpha Cognition Inc.$10.2M—202.2%$188.3MTSHATaysha Gene Therapies, Inc.$9.8M17.3%1,115.3%$1.3BCRISCuris Inc$9.4M13.4%80.3%$5.5MFATEFate Therapeutics Inc$6.6M51.2%2,051.1%$161.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR